Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 310

Sort by

Sort Order Select

Journal Articles

FV/FVa revealed

Josefin Ahnström

Blood (2021) 137 (22): 3011–3013.

https://doi.org/10.1182/blood.2021011573

Published: 2021

Journal Articles

Platelet protein S limits venous but not arterial thrombosis propensity by controlling coagulation in the thrombus

Sara Calzavarini, Raja Prince-Eladnani, François Saller, Luca Bologna, Laurent Burnier, Anne C. Brisset, Claudia Quarroz, Maria Desiré Reina Caro, Vladimir Ermolayev, Yasuhiro Matsumura, José A. Fernández, Tilman M. Hackeng, John H. Griffin, Anne Angelillo-Scherrer

Blood (2020) 135 (22): 1969–1982.

https://doi.org/10.1182/blood.2019003630

Published: 2020

Includes: Multimedia, Supplemental data

Journal Articles

TFPI blockade: removing coagulation’s brakes

Robert F. Sidonio, Jr, Karen L. Zimowski

Blood (2019) 134 (22): 1885–1887.

https://doi.org/10.1182/blood.2019002900

Published: 2019

Journal Articles

Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results

Amy D. Shapiro, Pantep Angchaisuksiri, Jan Astermark, Gary Benson, Giancarlo Castaman, Pratima Chowdary, Hermann Eichler, Victor Jiménez-Yuste, Kaan Kavakli, Tadashi Matsushita, Lone Hvitfeldt Poulsen, Allison P. Wheeler, Guy Young, Silva Zupancic-Salek, Johannes Oldenburg

Blood (2019) 134 (22): 1973–1982.

https://doi.org/10.1182/blood.2019001542

Published: 2019

Includes: Multimedia, Supplemental data

Journal Articles

Low factor V level ameliorates bleeding diathesis in patients with combined deficiency of factor V and factor VIII

Yanyan Shao, Wenman Wu, Guanqun Xu, Xuefeng Wang, Qiulan Ding

Blood (2019) 134 (20): 1745–1754.

https://doi.org/10.1182/blood.2018886069

Published: 2019

Includes: Supplemental data

Journal Articles

Protein S Coordinates the Inhibition of Prothrombinase By Tfpiα and Activated Protein C

Xian Li, PhD, Sara J Bidarian, Martha Sim, Xiaohong Song, Jeremy P. Wood, PhD

Blood (2019) 134 (Supplement_1): 2386.

https://doi.org/10.1182/blood-2019-130799

Published: 2019

Journal Articles

Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Severe Hemophilia a without Inhibitors: Results from the Phase 2 explorer5 Trial

Hermann Eichler, Pantep Angchaisuksiri, MD, Jan Astermark, MD PhD, Gary Benson, Katarina Cepo, Pratima Chowdary, MD, Ute Friedrich, PhD, Kaan Kavakli, Allison P Wheeler, MD, Johannes Oldenburg, MD PhD

Blood (2019) 134 (Supplement_1): 2417.

https://doi.org/10.1182/blood-2019-122300

Published: 2019

Journal Articles

Concizumab Subcutaneous Prophylaxis Improves Health-Related Quality-of-Life Measures in Patients with Congenital Hemophilia with Inhibitors: Phase 2 Trial Results

Xin Ying Lee, Katarina Cepo, Thomas Porstmann

Blood (2019) 134 (Supplement_1): 2419.

https://doi.org/10.1182/blood-2019-122827

Published: 2019

Journal Articles

Adeno-Associated Virus Mediated Delivery of a TFPI Antibody Restores Hemostasis in Mouse Model of Hemophilia

Swapnil Rakhe, MS, Reema Jasuja, PhD, Rajani Shelke, Anagha Sawant, Suryanarayan Somanathan, PhD, John E. Murphy, PhD, Debra D Pittman, MS

Blood (2019) 134 (Supplement_1): 3357.

https://doi.org/10.1182/blood-2019-130054

Published: 2019

Journal Articles

Identification of a Spontaneous Noncoding Mutation on Chromosome 18 Which Suppresses Thrombosis in Factor V Leiden Homozygous, TFPI Deficient Mice

Marisa A Brake, BSc, McKenzie A Allen, BSc, Guojing Zhu, MD, Amy E Siebert, PhD, Randal J Westrick, PhD

Blood (2019) 134 (Supplement_1): 483.

https://doi.org/10.1182/blood-2019-130936

Published: 2019

Journal Articles

The Tissue Factor Pathway Inhibitor Gamma Knockout Mouse Is a Better Model Than the Wild Type Mouse for Studying Tissue Factor-Related Human Diseases

Thomas J. Girard, Nina M. Lasky, Dhanalakshmi S. Anbukumar, George J. Broze, Jr.

Blood (2019) 134 (Supplement_1): 484.

https://doi.org/10.1182/blood-2019-130360

Published: 2019

Journal Articles

Characterization of the Interaction between Tissue Factor Pathway Inhibitor α (TFPIα) and Factor V Species

Teodolinda Petrillo, PhD, Cornelis Van 't Veer, PhD, Rodney M. Camire, PhD

Blood (2019) 134 (Supplement_1): 485.

https://doi.org/10.1182/blood-2019-130589

Published: 2019

Journal Articles

Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Hemophilia a or B with Inhibitors: Results from explorer4, a Phase 2, Randomized, Open-Label, Controlled Trial

Amy Shapiro, Giancarlo Castaman, MD, Katarina Cepo, Lone Hvitfeldt Poulsen, Christian Hollensen, Tadashi Matsushita, Guy Young, MD, Silva Zupancic-Salek, Victor Jimenez-Yuste

Blood (2019) 134 (Supplement_1): 1139.

https://doi.org/10.1182/blood-2019-122809

Published: 2019

Journal Articles

Hypercoagulability Biomarkers in a New Score Linked to Treatment Resistance for Multiple Myeloma Patients. the Roadmap-MM Study

Loula Papageorgiou, Despina Fotiou, BMBS, MA, Patrick Van Dreden, PhD, Laurent Garderet, MD PhD, Meletios A. Dimopoulos, MD, Ismail Elalamy, MD PhD, Mohamad Mohty, MD PhD, Grigoris Gerotziafas, MD PhD

Blood (2019) 134 (Supplement_1): 1913.

https://doi.org/10.1182/blood-2019-126954

Published: 2019

Journal Articles

Thrombin Generation Assay in Plasma from Hemophilia a Patients with or without Inhibitors on Concizumab Prophylaxis: Spiking with rFVIIa or aPCC

Marianne Kjalke, PhD, Mads Kjelgaard-Hansen, Søren Andersen, Ida Hilden

Blood (2019) 134 (Supplement_1): 3639.

https://doi.org/10.1182/blood-2019-122301

Published: 2019

Journal Articles

Effect of Sulfated NON-Anticoagulant Low Molecular Weight Heparin in Cancer and NON-Cancer Associated Thrombosis

Kavitha Godugu, PhD, Shymaa Mousa, Noureldien Hassan Elsayed Darwish, MDPhDBS, Shaker A Mousa, PhD BPharm, MBA, MSc

Blood (2019) 134 (Supplement_1): 3670.

https://doi.org/10.1182/blood-2019-130992

Published: 2019

Journal Articles

Laminin G Domains of Protein S Bind and Inhibit Fixa

Sabyasachi Chatterjee, PhD MSc, BSc, Amber Sylvain, Undergraduate Student, Satish Pilli, PhD, Whitney Fant, MS, Doerte R. Fricke, MS, Terry Watt, PhD, Rinku Majumder, PhD

Blood (2019) 134 (Supplement_1): 3624.

https://doi.org/10.1182/blood-2019-127112

Published: 2019

Journal Articles

Genetic Absence of Integrin alpha2b Improves Survival of Tissue Factor Pathway Inhibitor Null Mice but Results in Hydrocephalus Formation

Michelle Castillo, BS, Emily Ott, BS, Robert Wujek, BS, Liu Qiuli, MD, Kathleen Schmainda, PhD, Susan Cohen, MD, Rashmi Sood, PhD

Blood (2019) 134 (Supplement_1): 3626.

https://doi.org/10.1182/blood-2019-131811

Published: 2019

Journal Articles

Characterisation of Citrullinated TFPI and Truncated TFPI Constructs By PAD4 in Model and Plasma Systems

M.G.L. Christella D. Thomassen, Dennis P.L. Suylen, Tilman M. Hackeng, PhD, Rory R. Koenen, PhD

Blood (2019) 134 (Supplement_1): 2390.

https://doi.org/10.1182/blood-2019-131190

Published: 2019

Journal Articles

In Vitro and In Vivo Characterization of Marstacimab, an Anti-TFPI Antibody

Chuenlei Parng, PhD, Macy Jin, PhD, Matthew Holsti, PhD, Susan Benard, Swapnil Rakhe, MS, Sunita R. Patel-Hett, PhD, Alison Joyce, Rob Webster, Debra D Pittman, MS

Blood (2019) 134 (Supplement_1): 2391.

https://doi.org/10.1182/blood-2019-130327

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

FV/FVa revealed

Platelet protein S limits venous but not arterial thrombosis propensity by controlling coagulation in the thrombus

TFPI blockade: removing coagulation’s brakes

Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results

Low factor V level ameliorates bleeding diathesis in patients with combined deficiency of factor V and factor VIII

Protein S Coordinates the Inhibition of Prothrombinase By Tfpiα and Activated Protein C

Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Severe Hemophilia a without Inhibitors: Results from the Phase 2 explorer5 Trial

Concizumab Subcutaneous Prophylaxis Improves Health-Related Quality-of-Life Measures in Patients with Congenital Hemophilia with Inhibitors: Phase 2 Trial Results

Adeno-Associated Virus Mediated Delivery of a TFPI Antibody Restores Hemostasis in Mouse Model of Hemophilia

Identification of a Spontaneous Noncoding Mutation on Chromosome 18 Which Suppresses Thrombosis in Factor V Leiden Homozygous, TFPI Deficient Mice

The Tissue Factor Pathway Inhibitor Gamma Knockout Mouse Is a Better Model Than the Wild Type Mouse for Studying Tissue Factor-Related Human Diseases

Characterization of the Interaction between Tissue Factor Pathway Inhibitor α (TFPIα) and Factor V Species

Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Hemophilia a or B with Inhibitors: Results from explorer4, a Phase 2, Randomized, Open-Label, Controlled Trial

Hypercoagulability Biomarkers in a New Score Linked to Treatment Resistance for Multiple Myeloma Patients. the Roadmap-MM Study

Thrombin Generation Assay in Plasma from Hemophilia a Patients with or without Inhibitors on Concizumab Prophylaxis: Spiking with rFVIIa or aPCC

Effect of Sulfated NON-Anticoagulant Low Molecular Weight Heparin in Cancer and NON-Cancer Associated Thrombosis

Laminin G Domains of Protein S Bind and Inhibit Fixa

Genetic Absence of Integrin alpha2b Improves Survival of Tissue Factor Pathway Inhibitor Null Mice but Results in Hydrocephalus Formation

Characterisation of Citrullinated TFPI and Truncated TFPI Constructs By PAD4 in Model and Plasma Systems

In Vitro and In Vivo Characterization of Marstacimab, an Anti-TFPI Antibody

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only